SCHEMBL498159

SCHEMBL498159

CCOC(=O)C(C#N)(CC(=O)OC1CC(C)CCC1C(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.42
TRPM8 Q7Z2W7 1/20 0.40
CYP19A1 P11511 2/20 0.39
MAPT P10636 5/20 0.37
NPSR1 Q6W5P4 4/20 0.37
TSHR P16473 3/20 0.37
ALDH1A1 P00352 7/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPK1 P28482 4/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 2/20 0.35
USP2 O75604 1/20 0.35
MITF O75030 2/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
APAF1 O14727 1/20 0.33
XBP1 P17861 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334726 0.89 EPHX1 (0.45) EPHX1TRPM8CYP19A1MAPTNPSR1
SCHEMBL498400 0.84 CYP19A1 (0.43) EPHX1CYP19A1MAPTNPSR1TSHR
SCHEMBL498665 0.83 EPHX1 (0.43) EPHX1TRPM8CYP19A1MAPTNPSR1
SCHEMBL498183 0.83 EPHX1 (0.43) EPHX1TRPM8CYP19A1MAPTNPSR1
SCHEMBL498355 0.81 CYP19A1 (0.42) EPHX1CYP19A1MAPTNPSR1TSHR
SCHEMBL16015689 0.77 CYP19A1 (0.48) EPHX1TRPM8CYP19A1MAPTNPSR1
SCHEMBL3147326 0.74 EPHX1 (0.46) EPHX1CYP19A1MAPTNPSR1TSHR
SCHEMBL4343190 0.74 EPHX1 (0.46) EPHX1CYP19A1MAPTNPSR1TSHR
SCHEMBL4331089 0.74 CYP19A1 (0.46) EPHX1CYP19A1MAPTNPSR1TSHR
SCHEMBL13059722 0.70 CYP19A1 (0.41) EPHX1TRPM8CYP19A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2058300-B1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION DAINIPPON SUMITOMO PHARMA CO (JP) 2013-01-09 EP disclosed
US-8106230-B2 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-01-31 US disclosed
US-8030486-B2 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-10-04 US disclosed
US-20110046373-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION INAGAKI TAKASHI 2011-02-24 US disclosed
US-20100076203-A1 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation DAINIPPON SUMITOMO PHARMA CO., LTD. 2010-03-25 US disclosed
EP-2058300-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046373-A1 SUCCINIC ACID DIESTER DERIVATIVE, PROCESS FOR PRODUCTION THEREOF, AND USE OF THE DERIVATIVE IN THE PRODUCTION OF PHARMACEUTICAL PREPARATION SUCNR1, DLST, SHMT2 EPHX1 3382/4885TRPM8 1337/4885CYP19A1 533/4885
US-20100076203-A1 Succinic acid diester derivative, process for production thereof, and use of the derivative in the production of pharmaceutical preparation SUCNR1, DLST, SHMT2 EPHX1 3382/4885TRPM8 1337/4885CYP19A1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.